AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Byline: MARILYN ALVA
In the last few years, a single drug put Forest Laboratories on the same stage with some of the biggest pharmaceutical companies in the world.
Sales of that drug, the anti-depressant Celexa, rivaled those of Pfizer's Zoloft and GlaxoSmithKline's Paxil, among others.
Celexa's success in turn helped lift Forest's market cap to more than $25 billion, making it the largest specialty drug firm in the world.
"They had the right product, the right marketing message and a highly (motivated) sales force," said analyst David Steinberg of Deutsche Bank Securities, which doesn't have banking ties to Forest.
Problem is, Celexa's patent is due to expire early next year, clearing the way for generic copycats.
Rather than sit back and sulk, Forest is busy working on other drugs that could make up for Celexa's decline, including one that was recently approved to treat Alzheimer's disease.